Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
← catalyst calendarNCT03478462 · readout in 6 d
Sponsored by Cellectar Biosciences, Inc. (industry) · CLRB — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
8
Countries
Australia, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-30 | actual | When the study began enrolling |
| Primary completion | 2026-08-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-25 | estimated | The whole study's end, after follow-up |
| First posted | 2018-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pediatric Solid Tumor
- Pediatric Lymphoma
- Pediatric Brain Tumor
- DIPG
- Neuroblastoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Osteosarcoma
Intervention
- Drug: CLR 131 — also filed as I-131-CLR1404
Primary outcome
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLT)
measured up to 64 days
Permalink · CLRB's whole pipeline · Catalyst calendar · Every registered study · What changed